What is ARS Pharma?
Established in 2015 and headquartered in San Diego, California, ARS Pharma is dedicated to advancing the treatment of anaphylaxis. The company's core innovation lies in its intranasal epinephrine spray, which utilizes a unique absorption technology designed for rapid and effective intervention during allergic emergencies. This development targets life-threatening reactions to food, medications, and insect bites, offering a potentially more convenient and accessible alternative to traditional epinephrine auto-injectors. The company's trajectory suggests a strong focus on clinical development and market entry within the emergency medicine and allergy treatment sectors.
How much funding has ARS Pharma raised?
ARS Pharma has raised a total of $75M across 2 funding rounds:
Series C
$20M
Series D
$55M
Series C (2018): $20M with participation from Deerfield
Series D (2021): $55M led by Deerfield, SR One, and RA Capital Management
Key Investors in ARS Pharma
Deerfield
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy. The firm supports companies across the healthcare ecosystem with flexible funding models and drives innovation using AI, data, and market research.
SR One
SR One is a venture capital firm that invests in early-stage drug discovery and development companies. They provide capital and strategic guidance to help innovative biotechnology and pharmaceutical companies advance their pipelines.
RA Capital Management
RA Capital Management is a healthcare-focused investment manager that provides capital to public and private companies. They are known for their deep scientific understanding and their ability to support companies through various stages of development.
What's next for ARS Pharma?
The recent major strategic investment indicates ARS Pharma is poised for significant scaling and potential commercialization efforts. This capital infusion is likely to accelerate the company's clinical trial progression, regulatory submissions, and manufacturing scale-up. With a clear focus on a critical unmet medical need, ARS Pharma's next steps will likely involve demonstrating the efficacy and safety of its intranasal epinephrine spray to gain market approval and establish its position as a key player in the emergency allergy treatment landscape. Further strategic partnerships or funding rounds may follow as the company moves towards broader market penetration.
See full ARS Pharma company page
